Shawn E McCandless1, Jack A Yanovski2, Jennifer Miller3, Cary Fu4, Lynne M Bird5, Parisa Salehi6, Christine L Chan7, Diane Stafford8, M Jennifer Abuzzahab9, David Viskochil10, Sarah E Barlow11, Moris Angulo12, Susan E Myers13, Barbara Y Whitman13, Dennis Styne14, Elizabeth Roof4, Elisabeth M Dykens4, Ann O Scheimann15, Jaret Malloy16, Dongliang Zhuang16, Kristin Taylor16, Thomas E Hughes16, Dennis D Kim16, Merlin G Butler17. 1. UH Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio. 2. Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 3. University of Florida, Gainesville, Florida. 4. Vanderbilt University Medical Center, Nashville, Tennessee. 5. UCSD Rady Children's Hospital, San Diego, California. 6. Division of Endocrinology & Diabetes, Seattle Children's Hospital, Seattle, Washington. 7. Children's Hospital Colorado, Aurora, Colorado. 8. Children's Hospital Boston, Boston, Massachusetts. 9. Children's Hospital & Clinics of Minnesota, Saint Paul, Minnesota. 10. University of Utah, Salt Lake City, Utah. 11. Baylor College of Medicine, Houston, Texas. 12. Winthrop-University Hospital, Mineola, New York. 13. Saint Louis University School of Medicine, Saint Louis, Missouri. 14. UC Davis Children's Hospital, UC Davis Medical Center, Davis, California. 15. Baylor College of Medicine and Johns Hopkins School of Medicine, Baltimore, Maryland. 16. Zafgen, Inc., Boston, Massachusetts. 17. Departments of Psychiatry, Behavioral Sciences and Pediatrics, University of Kansas Medical Center, Kansas City, Kansas.
Abstract
AIMS: There are no treatments for the extreme hyperphagia and obesity in Prader-Willi syndrome (PWS). The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib. MATERIALS AND METHODS: Participants with PWS (12-65 years old) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Co-primary endpoints were the changes in hyperphagia [measured by Hyperphagia Questionnaire for Clinical Trials (HQ-CT); possible score 0-36] and weight by intention-to-treat. ClinicalTrials.gov registration: NCT02179151. RESULTS:One-hundred and seven participants were included in the intention-to-treat analysis: placebo (n = 34); 1.8 mg beloranib (n = 36); or 2.4 mg beloranib (n = 37). Improvement (reduction) in HQ-CT total score was greater in the 1.8 mg (mean difference -6.3, 95% CI -9.6 to -3.0; P = .0003) and 2.4 mg beloranib groups (-7.0, 95% CI -10.5 to -3.6; P = .0001) vs placebo. Compared with placebo, weight change was greater with 1.8 mg (mean difference - 8.2%, 95% CI -10.8 to -5.6; P < .0001) and 2.4 mg beloranib (-9.5%, 95% CI -12.1 to -6.8; P < .0001). Injection site bruising was the most frequent adverse event with beloranib. Dosing was stopped early due to an imbalance in venous thrombotic events in beloranib-treated participants (2 fatal events of pulmonary embolism and 2 events of deep vein thrombosis) compared with placebo. CONCLUSIONS:MetAP2 inhibition with beloranib produced statistically significant and clinically meaningful improvements in hyperphagia-related behaviours and weight loss in participants with PWS. Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity.
RCT Entities:
AIMS: There are no treatments for the extreme hyperphagia and obesity in Prader-Willi syndrome (PWS). The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib. MATERIALS AND METHODS:Participants with PWS (12-65 years old) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Co-primary endpoints were the changes in hyperphagia [measured by Hyperphagia Questionnaire for Clinical Trials (HQ-CT); possible score 0-36] and weight by intention-to-treat. ClinicalTrials.gov registration: NCT02179151. RESULTS: One-hundred and seven participants were included in the intention-to-treat analysis: placebo (n = 34); 1.8 mg beloranib (n = 36); or 2.4 mg beloranib (n = 37). Improvement (reduction) in HQ-CT total score was greater in the 1.8 mg (mean difference -6.3, 95% CI -9.6 to -3.0; P = .0003) and 2.4 mg beloranib groups (-7.0, 95% CI -10.5 to -3.6; P = .0001) vs placebo. Compared with placebo, weight change was greater with 1.8 mg (mean difference - 8.2%, 95% CI -10.8 to -5.6; P < .0001) and 2.4 mg beloranib (-9.5%, 95% CI -12.1 to -6.8; P < .0001). Injection site bruising was the most frequent adverse event with beloranib. Dosing was stopped early due to an imbalance in venous thrombotic events in beloranib-treated participants (2 fatal events of pulmonary embolism and 2 events of deep vein thrombosis) compared with placebo. CONCLUSIONS:MetAP2 inhibition with beloranib produced statistically significant and clinically meaningful improvements in hyperphagia-related behaviours and weight loss in participants with PWS. Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity.
Authors: M M Mazaheri; R D Rae-Seebach; H E Preston; M Schmidt; S Kountz-Edwards; N Field; S Cassidy; W Packman Journal: J Intellect Disabil Res Date: 2012-10-12
Authors: David A Stevenson; Janalee Heinemann; Moris Angulo; Merlin G Butler; Jim Loker; Norma Rupe; Patrick Kendell; Carol L Clericuzio; Ann O Scheimann Journal: Am J Med Genet A Date: 2007-03-01 Impact factor: 2.802
Authors: D D Kim; J Krishnarajah; S Lillioja; F de Looze; J Marjason; J Proietto; S Shakib; B G A Stuckey; J E Vath; T E Hughes Journal: Diabetes Obes Metab Date: 2015-03-31 Impact factor: 6.577
Authors: Roja Motaghedi; Elizabeth G Lipman; Jeannette E Hogg; Paul J Christos; Maria G Vogiatzi; Moris A Angulo Journal: Eur J Med Genet Date: 2010-10-20 Impact factor: 2.708
Authors: Maria A Rupnick; Dipak Panigrahy; Chen-Yu Zhang; Susan M Dallabrida; Bradford B Lowell; Robert Langer; M Judah Folkman Journal: Proc Natl Acad Sci U S A Date: 2002-07-29 Impact factor: 11.205
Authors: David A Stevenson; Janalee Heinemann; Moris Angulo; Merlin G Butler; Jim Loker; Norma Rupe; Patrick Kendell; Suzanne B Cassidy; Ann Scheimann Journal: J Pediatr Gastroenterol Nutr Date: 2007-08 Impact factor: 2.839
Authors: Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen Journal: Chem Rev Date: 2018-09-07 Impact factor: 60.622
Authors: Jie An; Liping Wang; Michael L Patnode; Vanessa K Ridaura; Jonathan M Haldeman; Robert D Stevens; Olga Ilkayeva; James R Bain; Michael J Muehlbauer; Erin L Glynn; Steven Thomas; Deborah Muoio; Scott A Summers; James E Vath; Thomas E Hughes; Jeffrey I Gordon; Christopher B Newgard Journal: JCI Insight Date: 2018-03-08
Authors: Mary Courtney Moore; Katie C Coate; Melanie Scott; Guillaume Kraft; James E Vath; Thomas E Hughes; Ben Farmer; Alan D Cherrington Journal: Am J Physiol Endocrinol Metab Date: 2020-01-28 Impact factor: 4.310
Authors: Melanie Demers; Sarah Sturtevant; Kevin R Guertin; Dipti Gupta; Kunal Desai; Benjamin F Vieira; Wenjing Li; Alexandra Hicks; Ayman Ismail; Bronner P Gonçalves; Giuseppe Di Caprio; Ethan Schonbrun; Scott Hansen; Faik N Musayev; Martin K Safo; David K Wood; John M Higgins; David R Light Journal: Blood Adv Date: 2021-03-09
Authors: Joseph Proietto; Jaret Malloy; Dongliang Zhuang; Mark Arya; Neale D Cohen; Ferdinandus J de Looze; Christopher Gilfillan; Paul Griffin; Stephen Hall; Thomas Nathow; Geoffrey S Oldfield; David N O'Neal; Adam Roberts; Bronwyn G A Stuckey; Dennis Yue; Kristin Taylor; Dennis Kim Journal: Diabetologia Date: 2018-07-11 Impact factor: 10.122